Univ.-Prof. Dr. med. Steffen Emmert

Univ.-Prof. Dr. med. Steffen Emmert
Klinische Tätigkeit: Allgemeine Ambulanz
Tumornachsorge
Phototherapie und -diagnostik
Genodermatosen
Muttermalsprechstunde
Weitere Tätigkeiten: Dermatologische Lehre, Klinische Fotodokumentation
Forschungsschwerpunkte: DNA-Reparatur und (UV-induzierte) Karzinogenese
Genodermatosen
Ausgewählte Publikationen: DNA-Reparatur
Internationale multizentrische Onkotherapiestudien
1. Emmert S., Kobayashi N., Khan S.G., and Kraemer K.H.; The
xeroderma pigmentosum group C gene leads to selective repair of
cyclobutane pyrimidine dimers rather than 6-4 photoproducts. The
Proceedings of the National Academy of Sciences USA, 2000; 97, 2151
- 2156.
2. Emmert S., Schneider T.D., Khan S.G., and Kraemer K.H.; The human
XPG gene: gene architecture, alternative splicing and single nucleotide
polymorphisms. Nucleic Acids Research, 2001; 29, 1443 – 1452.
3. Takebayashi Y., Pourquier P., Zimonjic D.B., Nakayama K., Emmert S.,
Ueda T., Urasaki Y., Kanzaki A., Akiyama S.I., Popescu N., Kraemer
K.H., and Pommier Y.; Antiproliferative activity of ecteinascidin 743 is
dependent upon transcription-coupled nucleotide-excision repair.
Nature Medicine, 2001; 7, 961 - 966.
4. Emmert S., Slor H., Busch D.B., Batko S., Albert B.A., Coleman D.,
Khan S.G., Abu-Libdeh B., DiGiovanna J.J., Cunningham B.B., Lee M.,
Crollick J., Inui H., Ueda T., Hedayati M., Grossman L., Shahlavi T.,
Cleaver J., and Kraemer K.H.; Relationship of neurologic degeneration
to genotype in three xeroderma pigmentosum group G patients. The
Journal of Investigative Dermatology, 2002; 118, 972 - 982.
5. Terunuma A., Ye J., Emmert S., Khan S.G., Kraemer K.H., and Vogel
J.C.; Ultraviolet light selection assay to optimize oligonucleotide
correction of mutations in endogenous xeroderma pigmentosum genes.
Gene Therapy, 2004; 11, 1729 - 1734.
6. Blankenburg S., Koenig I.R., Moessner R., Laspe P., Thoms K.M.,
Krueger U., Khan S.G., Westphal G., Berking C., Volkenandt M., Reich
K., Neumann C., Ziegler A., Kraemer K.H., Emmert S.; Assessment of 3
Xeroderma pigmentosum Group C Gene Polymorphisms and Risk of
Cutaneous melanoma: A Case-Control Study. Carcionogenesis, 2005;
26, 1085 - 1090.
7. Khan S.G., Oh K-S., Shahlavi T., Ueda T., Busch D.B., Inui H., Emmert
S., Imoto K., Muniz-Medina V., Baker C.C., DiGiovanna J.J., Schmidt
D., Khadavi A., Metin A., Gozukara E., Slor H., Sarasin A., Kraemer
K.H.; Reduced XPC DNA repair gene mRNA levels in clinically normal
parents of xeroderma pigmentosum patients. Carcinogenesis, 2006; 27,
84 - 94.
8. Oh K.-S., Khan S.G., Jaspers N.G.J., Raams A., Ueda T., Lehmann A.,
Friedmann P., Emmert S., Gratchev A., Lachlan K., Lucassan A., Baker
C.C., and Kraemer K.H.; Phenotypic heterogeneity in the XPB DNA

helicase gene (ERCC3): Xeroderma pigmentosum without and with
Cockayne syndrome. Human Mutation, 2006; 27, 1092 - 1103.
9. Emmert S., Wetzig T., Imoto K., Khan S.G., Oh KS., Laspe P.,
Zachmann K., Simon J.C., Kraemer K.H.; A novel complex
insertion/deletion mutation in the XPC DNA repair gene leads to skin
cancer in an Iraqi family. The Journal of Investigative Dermatology,
2006; 126, 2542 - 2544.
10. Emmert S., Leibeling D., Rünger T.M.; Syndrome mit genetischer
Instabilität: Modellerkrankungen zum Verständnis der (Haut-)
Kanzerogenese. Journal der Deutschen Dermatologischen
Gesellschaft, 2006; 4, 721 - 731.
11. Thoms KM., Kuschal C., Emmert S.; Lessons learned from DNA repair
defective syndromes. Experimental Dermatology, 2007; 16, 532 - 544.
12. Inui H., Oh KS., Nadem C., Metin A., Gozukara E., Emmert S., Slor H.,
Busch D., Khan SG., Baker C., Ueda T., DiGiovanna J., Tamura D.,
Seitz CS., Gratchev A., Chung KY., Chung HJ., Woodgate R.,
Schneider T., Kraemer KH.; Xeroderma variant patients from America,
Europe and Asia. Journal of Investigative Dermatology, 2008; in press.
Verhornungsstörungen
1. Emmert S., Küster W., Schauder S., Neumann C., and Ruenger T.M.;
Erythrokeratodermia progressiva symmetrica Darier-Gottron with
generalized expression. Der Hautarzt, 1998; 49, 666 - 671.
2. Emmert S., Küster W., Hennies, H.C., Zutt M., Haenssle H., Kretschmer
L., and Neumann C.; 47 patients in 14 families with the rare
genodermatosis keratosis punctata palmoplantaris Buschke-Fischer-
Brauer. European Journal of Dermatology, 2003; 13, 16 - 20.
3. Emmert S., Küster W., Zutt M., Hänssle H., Hallermann C., Kretschmer
L., and Neumann C.; A new family with the rare genodermatosis
keratosis punctata palmo-plantaris Buschke-Fischer-Brauer. Journal of
the American Academy of Dermatology; 2003; 49, 1166 - 1169.
4. Haenssle H., Finkenrath A., Hausser I., Oji V., Traupe H., Hennies HC.,
Neumann C., Emmert S.; Effective therapy of a severe
thermodysregulation by oral retinoids in a patient with recessive
congenital lamellar ichthyosis EM-type III. Clinical and Experimental
Dermatology, 2008; in press.
Melanom/Nävi
1. Ruenger T.M., Emmert S., Schadendorf D., Diem C., Epe B., and
Hellfritsch D.; Alterations of DNA repair in melanoma cell lines resistant
to cisplatin, fotemustine, or etoposide. The Journal of Investigative
Dermatology, 2000; 114, 34 - 39.
2. Emmert S., Zutt M., Haenssle H., Neumann C., and Kretschmer L.;
Inefficacy of vindesine monotherapy in advanced stage IV malignant
melanoma patients previously treated with other chemotherapeutic
agents. Melanoma Research, 2003; 13, 299 - 302.
3. Haenssle H.A., Vente C., Bertsch H.P., Rupprecht R., Abuzahra F.,
Junghans V., Ellinghaus B., Emmert S., Hallermann C., Rosenberger
A., and Neumann C.; Results of a surveillance programme for patients
at high risk of malignant melanoma using digital and conventional
dermoscopy. European Journal of Cancer Prevention, 2004; 13, 133 –
138.
4. Haenssle H.A., Krause S.W., Emmert S., Zutt M., Kretschmer L.,
Schmidberger H., Andreesen R., and Soruri A.; Hybrid cell vaccination

in metastatic melanoma: Clinical and immunologic results of a phase I/II
study. Journal of Immunotherapy, 2004; 27, 147 - 155.
5. Haenssle H.A., Krueger U., Vente C., Thoms K.M., Bertsch H.P., Zutt
M., Rosenberger A., Neumann C., Emmert S.; Results from an
observational trial: Digital epiluminescence microscopy follow-up of
atypical nevi increases the sensitivity and the chance of success of
conventional dermoscopy in detecting melanoma. The Journal of
Investigative Dermatology, 2006; 126, 980 - 985.